Kreitzer Anatol
Chief Discovery Officer
Kreitzer Anatol has filed 7 SEC Form 4 filings (15 transaction rows) across 1 company, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Aug 19, 2026.
On the most recent filing, Kreitzer Anatol is listed as Chief Discovery Officer at MapLight Therapeutics, Inc. Inside the rolling window, Kreitzer Anatol reported no open-market purchases and 5 open-market sales totaling $2.8M in MPLT. The largest disclosed transaction in the window is a sale of 45,422 MPLT shares on Apr 27, 2026, worth $1.3M.
Companies traded
Other insiders at MPLT
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.8M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kreitzer Anatol made?
Kreitzer Anatol has filed 7 SEC Form 4 filings (15 transaction rows) across 1 company since 2025.
Which companies does Kreitzer Anatol trade?
Kreitzer Anatol has filed SEC Form 4 disclosures for 1 company, including MPLT.
When was Kreitzer Anatol's most recent SEC Form 4 filing?
Kreitzer Anatol's most recent SEC Form 4 filing on Tracefour is dated Aug 19, 2026.
What is Kreitzer Anatol's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Kreitzer Anatol is listed as Chief Discovery Officer.
What is Kreitzer Anatol's total buy and sell value in the current window?
Inside the rolling retention window, Kreitzer Anatol bought $0 and sold $2.8M based on SEC Form 4 filings.
What was Kreitzer Anatol's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 45,422 MPLT shares on 2026-04-27, worth $1.3M, per SEC Form 4 filings.